Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideABTAbbott Laboratories
FinDog View：Neutral
LLYLilly (Eli)
FinDog View：Bullish
| Metric | ABT | LLY |
|---|
| Close | 106.20 | 1,417.54 |
| Market Cap | $184B | $1.34T |
| 1M | +7.46% | +22.51% |
| P/E (TTM) | 39.1 | 50.2 |
| Forward P/E | 17.6 | 26.3 |
| P/E 5-Yr Percentile | 99 | 28 |
| P/S | 3.8 | 16.8 |
| P/B | 3.6 | 39.6 |
| Dividend Yield | 1.98% | 0.75% |
| Latest Quarter Revenue | $11.2B | $24.4B |
| Revenue YoY | +7.8% | +38.6% |
| Gross Margin | 56.2% | 83.9% |
| Latest Quarter EPS | 0.61 | 7.22 |
| Avg Post-Earnings Move | ±1.6% | ±3.5% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.71% | 0.88% |
| 90-Day Net Insider Buying | −$46.9M | −$16.0M |
ABT · Revenue, Last 8 Quarters ($B)
LLY · Revenue, Last 8 Quarters ($B)
